To provide researchers, clinicians, and the people of Utah with the most advanced quantitative and molecular imaging technologies including radiopharmaceuticals and instrumentation to enable the highest quality research and assist clinicians in diagnosing disease and monitoring therapy.
Patients participating in clinical trials and receiving state of the art cancer care at the Huntsman Cancer Institute (HCI) will be provided with quantitative imaging methods and techniques to accurately stage disease and measure response to therapy. With the increasing number of oncologic therapeutic strategies currently available in clinical trials this has generated a need to have available reliable and reproducible methods for prediction and /or assessment of therapeutic response. The Center for Quantitative Cancer Imaging at HCI is responsible for assuring that the imaging performed on our patients is state of the art and of the highest quality.
History of the Center for Quantitative Cancer Imaging (CQCI)
Huntsman Cancer Institute at the University of Utah (HCI) and the University of Utah made commitments to develop a Molecular Imaging Program that supported the research and clinical efforts of HCI and the University. The program began with the purchase of a GE Advance PET scanner and later with the building of a cyclotron facility. In 2009 a dedicated PET imaging research facility was built housing the GE Advance PET scanner and a new research GE Discovery ST PET/CT scanner. In the spring of 2013 the GE Advance scanner was retired and a new GE Discovery PET/CT 710 time of flight scanner was installed. The currently available resources for molecular imaging within the Center for Quantitative Cancer Imaging are primarily oriented around capabilities in PET imaging. A complete and detailed listing of our infrastructure is provided elsewhere on this website. The infrastructure is state-of-the art and was initially focused on the production of Fluoro-2-deoxyglucose (FDG) and PET imaging of patients with cancer and for assessment of patients with dementia. Several other investigational research compounds are now available for research studies and listed below.
Current IND Imaging Agents
- IND 76,843 3’-deoxy-3’-[F 18]fluorothymidine:[F-18]FLT
- IND 104,035 [11C]-PIB (N-Methyl-[11C] 2-(41-methylaminophenyl)-6-hydroxybenzothiazole
- IND 109,760 18F-39-F-6-OH-BTA1 also known as 18FGE067 (Flutemetamol) or 18F-PIB
- IND 111,064 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole [18F]FMISO, FMISO
- IND 113,183 11C-Acetate or [C-11] Sodium Acetate
- IND 113,529 H215O ([O-15] Water)
- IND 113,858 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
- IND 120,130 [18F] Fluciclatide (GE [18F]AH111585)
In the summer of 2005 John M. Hoffman, MD was recruited to be the Director of the Molecular Imaging Program. The program has grown and expanded to encompass all aspects of quantitative cancer imaging. In the summer of 2013, Jeff Yap, PhD was recruited as the Associate Director of the Center to expand efforts in tumor metrics for patients on clinical trials and expansion of preclinical imaging. The name of the Molecular Imaging Program was changed to the Center for Quantitative Cancer Imaging in the summer of 2013 to more appropriately reflect the broad efforts of imaging taking place within the center and at HCI. An organizational chart of the center is available.